Cystic Fibrosis Clinical Trial
— STURDYOfficial title:
Estrogen Supplementation and Bone Health in Women With CF (STURDY)
The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are: - How do different forms of hormonal contraception (e.g. birth control pill or other progesterone only methods) impact bone health? - Is a study of transdermal estradiol (estrogen skin patches) feasible in this group? - How does transdermal estradiol impact bone health and quality of life? Participants in the observational study will have three study visits (baseline, 6 months, and 12 months). At all visits, participants will have blood drawn and will complete questionnaires. At the baseline and 12 month visits, participants will additionally have x-rays and DXAs (bone density assessment). Between visits, participants will complete brief questionnaires. Researchers will compare various measurements over time to assess the impact of different forms of hormonal contraception. Participants in the feasibility sub-study will apply transdermal estradiol patches once weekly for 12 months, fill out brief quality-of-life surveys in between study visits, and complete blood draws and questionnaires at four study visits (baseline, 3 months, 6 months, and 12 months). The participants will also have x-rays and DXAs performed at the baseline and 12 month visits. Researchers will examine changes in various measurements to determine the impact of transdermal estradiol.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 0 Years to 100 Years |
Eligibility | Observational Study: Inclusion Criteria: - CF Diagnosis - Females who have had at least 1 menstrual cycle - Planning to use same formulation of estrogen supplementation (or none) for duration of study Exclusion Criteria: - Use of anti-osteoporosis therapy including anti-resorptives such as bisphosphonates or anabolic agents such as teriparatide or denosumab - Conditions in which bone loss is known to be present or expected to occur, such as lactation - Pregnant or planning to become pregnant - In the opinion of the CF care team or study investigators participant should not participate in the study - Inability to provide informed consent/assent Feasibility Sub-Study: Inclusion Criteria: - All of above and - <35 years old - At least 2 years after first menstrual cycle - Symptoms of low estrogen and/or low serum estradiol levels (< 50 pg/mL) Exclusion Criteria: - All of above and - Contraindications to transdermal estradiol - Current use of systemic estrogen (such as estrogen-containing oral contraceptive pill) - Previous lung or liver transplant - Use of chronic systemic glucocorticoids - Severe vitamin D deficiency (serum 25(OH)D < 6 ng/mL) - Conditions increasing risk of clot: history of previous deep vein thrombus or pulmonary embolism, current immobility, current peripherally inserted central catheter or mediport, known hypercoagulable condition - Baseline study visit falls between 1 and 8 weeks after initiation of CF transmembrane receptor (CFTR) modulator - Currently in pulmonary exacerbation - Recent antibiotic use within the past 4 weeks for an acute pulmonary exacerbation - Unwilling or unable to use a non-estrogen containing method of contraception such as barrier, abstinence, or progesterone-only method |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | Cystic Fibrosis Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Study procedure completion rate | Percentage of participants enrolled in study who complete all study procedures. | Evaluated at completion of study, approximately two years | |
Other | Acceptability as determined by participant report | Acceptability during study participation by 5 point Likert scale, with a score or 3 or greater considered acceptable. | Across 12 months of study participation per participant | |
Primary | Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA) | Baseline and 12 months | ||
Secondary | Change in serum procollagen type I intact N-terminal propeptide (P1NP) levels (mcg/L) | P1NP is a marker of bone turnover. | Baseline and 12 months | |
Secondary | Change in serum C-terminal telopeptide of type I collagen (CTX-1) levels (pg/mL) | CTX-1 is a marker of bone turnover. | Baseline and 12 months | |
Secondary | Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire | CFRSD-CRISS is a brief survey to assess quality of life of people with cystic fibrosis that will be taken by participants twice per month. The questionnaire is scored from 0-100 with higher scores indicating increased symptom severity. | Baseline and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |